Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript
All right. Let's go ahead and get started. Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Malcolm Kuno, Priyanka Grover and [Marea Hall].
Our next presenting company is Ultragenyx, and presenting on behalf of the company, we have CEO, Emil Kakkis. Emil?
Thank you. Good to see all of you today. It's been my 20th, so it's 42, but I'm -- my 20th here. So it's great to be here and give you an update on Ultragenyx. We have a big year ahead. 2024 is a big year, a lot of build up, putting us in good position, and we'll talk a little about that update today.
Forward-looking statement for all of you.
Now, I think if you look at what we've been doing in our 10th year from going public, we're just coming up to our 10th anniversary of going public, I think we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
